Boulding Mark Elliott 4
4 · PTC THERAPEUTICS, INC. · Filed Jul 8, 2026
Research Summary
AI-generated summary of this filing
PTC Therapeutics CLO Mark Boulding Exercises Options, Sells Shares
What Happened
Mark Elliott Boulding, Executive Vice President and Chief Legal Officer of PTC Therapeutics (PTCT), exercised options to acquire 5,079 shares (2,266 @ $39.42 and 2,813 @ $46.54) for aggregate exercise payments of $220,243. On the same day (July 6, 2026) he sold 5,079 shares in multiple open-market trades for aggregate proceeds of approximately $432,118 (weighted-average prices reported across several trade ranges). The Form 4 was filed July 8, 2026 (timely).
Key Details
- Transaction date: July 6, 2026; Form 4 filed July 8, 2026.
- Option exercises (code M): 2,266 shares at $39.42 (cost $89,326) and 2,813 shares at $46.54 (cost $130,917).
- Market sales (code S): total 5,079 shares sold in multiple trades for about $432,118 (weighted-average prices reported between ~$82.76 and $86.73 per share across different trade groups).
- Two additional derivative disposals are reported at $0.00 for 2,226 and 2,813 shares (these typically reflect shares withheld or surrendered in connection with option exercises).
- Footnotes: sales were executed in multiple trades (weighted averages provided; issuer/SEC may request per-trade breakdown). One transaction was made pursuant to a written Rule 10b5-1 trading plan adopted Sept 10, 2025. Option grant and vesting info: one option granted Jan 5, 2023 (vesting schedule per F6) and one granted Jan 3, 2025 (vesting per F7).
- Shares owned after the transactions: not specified in the provided excerpt of the filing.
Context
This filing shows option exercises combined with same-day open-market sales — a common pattern when executives exercise vested options and sell shares to cover exercise costs, taxes or diversify. The 10b5-1 plan and the multiple-trade weighted-average disclosures indicate some sales were pre-planned and executed across several trades rather than a single block.
Insider Transaction Report
- Exercise/Conversion
Common Stock
[F1]2026-07-06$39.42/sh+2,266$89,326→ 107,538 total - Sale
Common Stock
[F1][F2]2026-07-06$83.10/sh−313$26,010→ 107,225 total - Sale
Common Stock
[F1][F3]2026-07-06$84.41/sh−833$70,314→ 106,392 total - Sale
Common Stock
[F1][F4]2026-07-06$85.84/sh−519$44,551→ 105,873 total - Sale
Common Stock
[F1][F5]2026-07-06$86.38/sh−601$51,914→ 105,272 total - Exercise/Conversion
Common Stock
[F1]2026-07-06$46.54/sh+2,813$130,917→ 108,085 total - Sale
Common Stock
[F1][F2]2026-07-06$83.10/sh−387$32,160→ 107,698 total - Sale
Common Stock
[F1][F3]2026-07-06$84.41/sh−1,036$87,449→ 106,662 total - Sale
Common Stock
[F1][F4]2026-07-06$85.84/sh−645$55,367→ 106,017 total - Sale
Common Stock
[F1][F5]2026-07-06$86.38/sh−745$64,353→ 105,272 total - Exercise/Conversion
Stock Option (Right to Buy)
[F1][F6]2026-07-06−2,226→ 4,532 totalExercise: $39.42Exp: 2033-01-04→ Common Stock (2,266 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
[F1][F7]2026-07-06−2,813→ 28,125 totalExercise: $46.54Exp: 2035-01-02→ Common Stock (2,813 underlying)
Footnotes (7)
- [F1]This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025.
- [F2]This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $82.76 to $83.68 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- [F3]This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $83.98 to $84.94 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- [F4]This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $85.18 to $86.17 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- [F5]This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $86.18 to $86.73 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- [F6]This option was granted on January 5, 2023 and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024.
- [F7]This option was granted on January 3, 2025, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2026, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2026.